(CercleFinance.com) – Novartis announced on Friday that the US Food and Drug Administration (FDA) had approved a new pharmaceutical production site for Pluvicto, its new treatment for prostate cancer, based in Indianapolis.
This ultra-modern unit, which has an area of 6,500 m2, will be entirely dedicated to the manufacture of radioligand therapies. This is the group’s second factory in the United States, after that in Millburn (New Jersey).
The site should allow the laboratory to meet growing demand on the American market, and even in Canada, since the Italian site in Ivrea must also supply the international market.
The one in Zaragoza (Spain) is only intended to supply markets outside the United States.
With these four production sites, Novartis believes it will be able to generate a production of around 250,000 doses of radioligands in 2024 and for the years to come.
The company recalls that it is currently conducting several clinical trials on the effectiveness of radioligands in other cancers (breast, colon, lung and pancreas, among others).
Copyright (c) 2024 CercleFinance.com. All rights reserved.